Send us Feedback

Repros Therapeutics (RPRX)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Repros (RPRX) Enters $11.1M Direct Placement
StreetInsider.com  Jan 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Repros+%28RPRX%29+Enters+%2411.1M+Direct+Placement/7113842.html for the full story.
Repros Announces Registered Direct Offering of Approximately $11.1 Millon
Globe Newswire  Jan 27  Comment 
THE WOODLANDS, Texas, Jan. 27, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has entered into definitive agreements with certain institutional investors, including certain existing shareholders, to sell an
Repros (RPRX) Submits Request to Withdrawal S-1 Filing, Cites Market Conditions
StreetInsider.com  Jan 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Repros+%28RPRX%29+Submits+Request+to+Withdrawal+S-1+Filing%2C+Cites+Market+Conditions/7080978.html for the full story.
Repros Therapeutics Files to Withdraw S-1 Filed on December 19, 2011; Had Filed to Sell 5.75M Shares
Benzinga  Jan 13  Comment 
Repros' IND for Proellex-V Accepted By the FDA
Benzinga  Jan 4  Comment 
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced its Investigational New Drug Application for Proellex-V, or vaginally delivered Proellex, has been accepted by the FDA. The indication identified in the new IND is for the use of Proellex-V...
Repros (RPRX) Completes Oral Proellex Phase 2; Says Lower Does Avoid Adverse Effects of Higher Doses
StreetInsider.com  Jan 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Repros+%28RPRX%29+Completes+Oral+Proellex+Phase+2%3B+Says+Lower+Does+Avoid+Adverse+Effects+of+Higher+Doses/7050826.html for the full story.
Donald Tredway MD, PhD, Joins Repros as Chief Medical Officer
Globe Newswire  Jan 3  Comment 
THE WOODLANDS, Texas, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the Company has hired Donald Tredway as its Chief Medical Officer. Dr. Tredway joined Serono, Inc. in 2000 as a Medical Director in the
Repros Receives Official FDA Minutes From Type C Meeting Held on 12/13/11 Confirming Path Forward for Androxal(R)
Globe Newswire  Dec 27  Comment 
THE WOODLANDS, Texas, Dec. 27, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the Company has received the official FDA minutes from its recent Type C meeting held with the joint divisions of urologic (DRUP) and
Repros (RPRX) Receives Minutes from FDA Type C Meeting for Androxal
StreetInsider.com  Dec 27  Comment 
Top-Line Phase 2b Data Indicate Androxal(R) Raises Testosterone Equivalent to Testim Without Impairing Spermatogenesis
Globe Newswire  Dec 22  Comment 
Statistically significant and clinically relevant improvement in testosterone production observed versus placebo and equivalent to an approved topical testosterone product Androxal® maintained sperm counts while Testim reduced counts in a
Repros (RPRX) Files 5.75M Common Shelf
StreetInsider.com  Dec 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Repros+%28RPRX%29+Files+5.75M+Common+Shelf/7032080.html for the full story.
Repros Meets With the Divisions of Urologic and Endocrinologic Products at FDA to Plan Direction of Phase 3 Program for Androxal(R)
Globe Newswire  Dec 14  Comment 
THE WOODLANDS, Texas, Dec. 14, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided a regulatory update for its Androxal program following a joint meeting with the Divisions of Urologic and Endocrinologic Products at the




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/Repros_Therapeutics_(RPRX)"
Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki